布格利单抗(Budigalimab) - 药物靶点：PD-1_在研适应症：转移性非鳞状非小细胞肺癌，不可切除的肝细胞癌，转移性尿路上皮癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Budigalimab (USAN/INN)、ABBV-181、PR 1648817

+ [2]

靶点

PD-1

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [4]

在研适应症

转移性非鳞状非小细胞肺癌不可切除的肝细胞癌转移性尿路上皮癌+ [20]

非在研适应症

晚期结直肠腺癌晚期子宫内膜癌输卵管癌+ [7]

原研机构

在研机构

非在研机构

权益机构

Idera Pharmaceuticals, Inc.

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 13413797H

来源: *****

Sequence Code 13413826L

来源: *****

关联

33

项与布格利单抗相关的临床试验

CTR20250545

/ Recruiting临床2期

一项在局部晚期不可切除或转移性胃、胃食管连接部或食道腺癌受试者中评价ABBV-400 联合氟尿嘧啶、甲酰四氢叶酸和Budigalimab 作为一线治疗的安全性、有效性和最佳剂量的II 期随机研究（AndroMETa-GEA-977）

‐ 评价ABBV-400联合5-FU、LV和Budigalimab的安全性和耐受性。 ‐ 选择ABBV-400联合5-FU、LV和Budigalimab的推荐III期临床试验剂量（RP3D）。 ‐ 根据无进展生存期（PFS）和客观缓解（OR），评价ABBV-400联合5-FU、LV和Budigalimab的有效性。 ‐ 评估ABBV-400联合氟尿嘧啶（5-FU）、甲酰四氢叶酸（LV）和Budigalimab在剂量递增部分的剂量限制性毒性（DLT）。 ‐ 根据缓解持续时间（DoR）、疾病控制（DC）和总生存期（OS），评价ABBV-400联合5-FU、LV和Budigalimab的有效性。 ‐ 评价ABBV-400联合5-FU、LV和Budigalimab的药代动力学（PK）。

开始日期2025-08-01

申办/合作机构

艾伯维医药贸易（上海）有限公司

[+2]

CTIS2024-514465-18-00

/ Recruiting临床1/2期

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536) - M24-536

开始日期2025-04-29

申办/合作机构

AbbVie Deutschland GmbH & Co. KG

NCT06772623

/ Recruiting临床1/2期

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 132 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

开始日期2025-03-06

申办/合作机构

AbbVie, Inc.

100 项与布格利单抗相关的临床结果

登录后查看更多信息

100 项与布格利单抗相关的转化医学

登录后查看更多信息

100 项与布格利单抗相关的专利（医药）

登录后查看更多信息

11

项与布格利单抗相关的文献（医药）

2025-10-03·MEDICINE

Global safety profile of PD-1/PD-L1 inhibitors in hepatic autoimmune disorders: A global disproportionality analysis

Article

作者: Hwang, Jiyoung ; Kong, Jaehyun ; Yon, Dong Keon ; Cho, Jaehyeong ; Park, Jaeyu ; Oh, Jeongseon ; Kim, Tae Hyeong ; Kim, Tae Hyeon

The increasing use of programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors in cancer therapy has raised concerns regarding immune-related adverse events. However, global pharmacovigilance studies on autoimmune diseases remain scarce. This study aimed to evaluate the signal detection between PD-1/PD-L1 inhibitors and hepatic autoimmune disorders. A global pharmacovigilance study was conducted using data from individual case safety reports. The analysis centered on PD-1/PD-L1 inhibitors, classified by Anatomical Therapeutic Chemical codes (e.g., atezolizumab, avelumab, budigalimab, cemiplimab, dostarlimab, durvalumab, nivolumab, pembrolizumab, sintilimab, spartalizumab, and tislelizumab). Hepatic autoimmune disorders were defined based on MedDRA Version 26.0 (Maintenance and Support Services Organization, McLean). Disproportionality analyses were performed using reporting odds ratios with 95% confidence intervals and information components (ICs), with IC0.25, to evaluate potential signal detection. A total of 1401 reports of hepatic autoimmune disorders associated with PD-1/PD-L1 inhibitors were identified. Nivolumab (59.89%) and pembrolizumab (27.62%) accounted for the highest reports. Notably, nivolumab (reporting odds ratio, 117.52 [95% confidence interval, 109.52–126.10]; IC, 6.67 [IC0.25, 6.60]) and pembrolizumab (55.69 [50.31–61.64]; 5.65 [5.55]) showed the notable reporting signals, followed by cemiplimab, atezolizumab, durvalumab, avelumab, sintilimab, and tislelizumab. Subgroup analysis showed a stronger signal for hepatic autoimmune disorders in males than in females treated with PD-1/PD-L1 inhibitors. Additionally, the mean time to onset was 22.90 days (standard deviation: 81.66), although some reports presented with substantially delayed onset. Most PD-1/PD-L1 inhibitors showed pharmacovigilance signals for hepatic autoimmune disorders, particularly nivolumab and pembrolizumab. Although our findings do not permit causal inference, these findings underscore the necessity for sustained hepatic monitoring, risk stratification, and appropriate therapeutic management.

2022-10-01·Annals of oncology : official journal of the European Society for Medical Oncology

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Article

作者: Chaput, N ; Le Loarer, F ; Tselikas, L ; Besse, B ; Fontan, L ; Roubaud, G ; Peyraud, F ; Italiano, A ; Auzanneau, C ; Cabart, M ; Barlesi, F ; Cousin, S ; Danlos, F-X ; Bodet, D ; Soria, J-C ; Nafia, I ; Bessede, A ; Guégan, J-P ; Planchard, D ; Even, C ; Marabelle, A ; Khettab, M ; Chomy, F

BACKGROUND:

The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the systemic approach to cancer treatment. Most patients receiving ICIs, however, do not derive benefits. Therefore, it is crucial to identify reliable predictive biomarkers of response to ICIs. One important pathway in regulating immune cell reactivity is L-arginine (ARG) metabolism, essential to T-cell activation. We therefore aimed to evaluate the association between baseline plasma ARG levels and the clinical benefit of ICIs.

PATIENTS AND METHODS:

The correlation between ARG levels and clinical ICI activity was assessed by analyzing plasma samples obtained before treatment onset in two independent cohorts of patients with advanced cancer included in two institutional molecular profiling programs (BIP, NCT02534649, n = 77; PREMIS, NCT03984318, n = 296) and from patients in a phase 1 first-in-human study of budigalimab monotherapy (NCT03000257). Additionally, the correlation between ARG levels and ICI efficacy in preclinical settings was evaluated using a syngeneic mouse model of colorectal cancer responsive to ICIs. Using matched peripheral blood mononuclear cell (PBMC) plasma samples, we analyzed the correlation between ARG levels and PBMC features through multiplexed flow cytometry analysis.

RESULTS:

In both discovery and validation cohorts, low ARG levels at baseline (<42 μM) were significantly and independently associated with a worse clinical benefit rate, progression-free survival, and overall survival. Moreover, at the preclinical level, the tumor rejection rate was significantly higher in mice with high baseline ARG levels than in those with low ARG levels (85.7% versus 23.8%; P = 0.004). Finally, PBMC immunophenotyping showed that low ARG levels were significantly associated with increased programmed death-ligand 1 expression in several immune cell subsets from the myeloid lineage.

CONCLUSIONS:

We demonstrate that baseline ARG levels predict ICI response. Plasma ARG quantification may therefore represent an attractive biomarker to tailor novel therapeutic regimens targeting the ARG pathway in combination with ICIs.

2022-04-01·Journal of immunotherapy (Hagerstown, Md. : 1997)4区 · 医学

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

4区 · 医学

Article

作者: Tribouley, Catherine ; McLaughlin, Robert Tyler ; Masica, David L. ; Sheridan, James ; Vosganian, Greg ; Englert, Stefan ; Turan, Tolga ; Guo, Claire ; Zhang, Chun ; Afar, Daniel ; Lambert, Stacie L. ; Fang, Yuni

Budigalimab, a novel anti–PD-1 monoclonal antibody, demonstrated efficacy and biomarker pharmacodynamics in patients with head and neck squamous cell carcinoma (HNSCC) or non–small cell lung cancer (NSCLC) consistent with those reported by other PD-1 inhibitors. Herein are presented additional outcomes of biomarker analyses from the phase 1 study of budigalimab monotherapy in patients with HNSCC and NSCLC (NCT03000257). PD-1 inhibitor naive patients with advanced HNSCC (n=41) or NSCLC (n=40) received budigalimab intravenously at 250 mg every 2 weeks (Q2W) or 500 mg Q4W until progression. Archival tumor specimens were evaluated by immunohistochemistry for CD8 and tumor PD-1 ligand 1 (PD-L1) expression, RNA, and whole-exome sequencing. Serum and whole blood samples were acquired at baseline and at select on-treatment time points. As of October 2019, best overall response of 15% in HNSCC and 18% in NSCLC was observed in all treated patients; both cohorts reported responses in PD-L1+ and PD-L1– tumors. Treatment with budigalimab was associated with increases in multiple soluble biomarkers including interferon gamma-induced chemokines. Expanded overall T-cell counts, total CD8 T-cell counts, and percentages of CD8+CD45RA–CD62L– effector memory T cells were observed at cycle 1, day 15 in responders. Univariate analysis demonstrated an association between prolonged progression-free survival and higher tumor mutational burden/neoantigen load, smaller tumor size, lower platelet-lymphocyte ratios, lower CCL23, lower colony-stimulating factor 1, and lower interleukin-6 levels at baseline. The biomarker analysis presented herein identified additional early pharmacodynamic biomarkers associated with anti–PD-1 activity and improved clinical responses to budigalimab in patients with advanced HNSCC and NSCLC.

24

项与布格利单抗相关的新闻（医药）

2025-10-29

·FierceBiotech

AbbVie halts development of Dragonfly cancer asset midflight

Alongside the AbbVie partnership, buzzy Dragonfly has also taken flight with Merck, Gilead and Bristol Myers Squibb.\n AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago pharma confirmed to Fierce Biotech.“We have terminated clinical activity around ABBV-303,” the spokesperson said, alluding to a phase 1 solid tumor trial of the natural killer (NK) cell engager. “However, our partnership with Dragonfly is still ongoing.”The study was terminated in light of “strategic considerations,\" according to its entry on the federal trial database clinicaltrials.gov. AbbVie and Dragonfly were testing ABBV-303 alone and in combination with AbbVie\'s anti-PD-1 antibody budigalimab (ABBV-181).Dragonfly did not respond to multiple requests for comment from Fierce. ABBV-303 was the first asset from the AbbVie-Dragonfly team-up to hit the clinic, triggering a milestone payment for Dragonfly in March 2024. The duo forged their pact in 2019 and expanded it in 2022 to include additional targets, with a focus on oncology and autoimmune diseases.AbbVie was studying the candidate in solid tumors expressing c-Met, the company spokesperson said, which is a receptor protein commonly found on the surface of tumor cells.“This termination does not impact our commitment to continue advancing c-Met targeted therapies,” the spokesperson added.Dragonfly’s pipeline is packed with Big Pharma collaborations and a clutch of wholly owned assets, the most advanced of which is DF1001, a HER2-targeting NK cell engager currently in a phase 1/2 trial for non-small cell lung cancer and metastatic breast cancer.Alongside the AbbVie partnership, buzzy Dragonfly has also taken flight with Merck, Gilead and Bristol Myers Squibb, with BMS also once dumping an asset back into Dragonfly’s pond.

引进/卖出临床1期临床终止蛋白降解靶向嵌合体抗体药物偶联物

2025-10-21

·百度百家

PD-1单抗首次助力艾滋病停药控毒8个月，改变终身服药命运有多近？

一天不吃药，病毒就卷土重来——这是数千万艾滋病感染者的日常。可最近一项发表于《自然医学》的新研究，让“终身服药”这道枷锁出现了松动的迹象。一种原本用于癌症治疗的免疫疗法，在部分HIV感染者中实现了停药后长达8个月病毒未反弹。这意味着什么？对普通患者和家庭又能带来哪些具体变化？抗逆录病毒疗法（ART）是目前控制HIV最有效的方法，但它并不能清除体内所有病毒。即使血液检测不到，HIV依然会藏在某些免疫细胞里，一旦停止用药，这些“潜伏部队”很快复苏。背后的关键难题，是慢性感染让人体免疫系统里的CD8+T细胞逐渐疲惫无力，而这些细胞表面的PD-1蛋白像极了一只踩下去的刹车，让本该冲锋陷阵的卫士们变得束手无策。科学家们想出了一个巧妙办法既然问题出在“刹车”，那就试着把它松开。本次研究用到的是Budigalimab，这是一种抗PD-1单克隆抗体，可以解除CD8+T细胞上的抑制信号，相当于给身体自带防御系统打了一针强心剂。临床试验分两步走先让一组患者继续按常规ART治疗，同时注射不同剂量的新型单抗，然后观察他们在停掉ART后体内病毒是否反弹；再换另一组，从第一天直接停止口服ART，只靠定期注射10mg Budigalimab，并密切监测12周。结果令人振奋。在接受低剂量、短周期（远低于癌症用量）的Budigalimab注射后，有2名参与者在204天和252天内始终保持了良好的病毒控制，不需要恢复传统口服方案。他们都不是所谓的“精英控制者”（指极少数不用吃药也能长期压制HIV的人），而是普通患者。这为今后的间歇性或有限周期治疗提供了现实可能。安全性同样备受关注。此次实验采用远低于肿瘤领域标准的小剂量，仅有2例出现轻微且可逆性的甲状腺相关副作用，没有严重不良事件发生。这一点对长期管理慢性疾病至关重要，因为只有风险足够小，才能考虑更广泛推广。机制上这类PD-1抑制剂属于免疫检查点抑制类新型生物医药，它与传统外源攻击型方案不同，更像是在帮身体自己修好武器库，把失去斗志的战士重新唤醒。如果未来可以将这种疗法与其他创新技术结，比如激活潜伏期HIV或使用广谱中和抗体，也许距离真正意义上的治愈又近一步。对于每位被困在每日吃药、担心漏服副作用中的人来说，“年度强化针”这样的设想，无疑会大幅减轻心理压力，也可能减少因长期高负荷用药导致的一系列健康隐患。但任何新技术普及，都绕不开现实考验。例如高昂费用、医保覆盖范围，以及尚需积累的大规模安全数据等，都决定着它何时能走进寻常百姓家门口诊室。目前所有已知成功案例仍属早期探索阶，还无法替代现行标准方案，自行停改处方存在巨大风险，应严格遵循医生指导，不可盲目跟风尝试。回头每一次医学突破都曾经历从“小概率奇迹”到“大众福音”的漫长过程。从每天按闹钟吞下一把胶囊，到未来也许一年只需几次强化针，人类与艾滋病这场拉锯战正悄然进入新的篇章。而你我所关心的不只是科技进步，更是那些实实在在影响生活质量的小改变——比如终于可以安心计划一次说走就走、不再担忧漏掉哪一顿饭后的那粒小片蓝色胶囊。如果说希望是什么，大概就是这种正在变得触手可及的新选择吧。怎么看这事？评论区交流。

免疫疗法

2025-10-18

·生物世界

Nature Medicine：首次人体实验，PD-1单抗治疗艾滋病

撰文丨王聪编辑丨王多鱼排版丨水成文艾滋病（AIDS），全称为获得性免疫缺陷综合征，是由人类免疫缺陷病毒（HIV）感染所引起的免疫系统进行性衰竭的疾病阶段。据统计，目前全世界有约有 4000 万人感染了 HIV 病毒，这导致艾滋病成为全球公共卫生的重要威胁。抗逆转录病毒疗法（ART）是通过联合使用多种抗逆转录病毒药物来抑制 HIV 病毒复制的标准治疗方案，能够将 HIV 病毒载量抑制在低水平，从而有效降低传播风险以及疾病进展和死亡风险。然而，ART 并不能治愈患者，持续的低水平炎症依然存在，合并症风险以及长期治疗相关的毒副作用也依然存在，此外，ART 疗法需要每天服药，这对用药依从性来说颇具挑战性。如果能够实现一次给药，长期持续抑制 HIV 病毒，将从根本上改变当前的 HIV 治疗模式，并显著改善感染者的的生活。 BudigalimabBudigalimab (ABBV 181; PR 1648817) 是一种靶向程序性细胞死亡蛋白 1 (PD-1)的人源化单克隆抗体，具有Fc突变，可减少Fc受体相互作用和效应因子抑制作用 2025 年 10 月 15 日，加拿大麦吉尔大学、艾伯维（AbbVie）公司的研究人员在国际顶尖医学期刊 Nature Medicine 上发表了题为：Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study 的研究论文。该论文报告了抗 PD-1 单抗 Budigalimab 在 HIV 感染者中的随机、安慰剂对照的 1b 期临床试验数据，这也是使用抗 PD-1 单抗治疗 HIV 感染者的首次人体临床试验，该临床试验达到了预先设定的终点，初步展示了安全性以及“无 ART 控制 HIV”的潜力。慢性 HIV-1 感染会，导致免疫耗竭和 T 细胞响应减弱，而 PD-1 抑制剂为在不使用抗逆转录病毒疗法（ART）的情况下通过逆转这些影响来实现病毒控制提供了一种潜在方法。 Budigalimab 是艾伯维（AbbVie）开发的一款人源化抗 PD-1 单克隆抗体。在这项随机、双盲、多中心、安慰剂对照的 1b 期临床试验中，研究团队对 HIV 感染者（n=41）进行了多次低剂量静脉注射治疗，第 1 阶段：2 毫克剂量（n=10）、10 毫克剂量（n=10）、安慰剂组（n=5），每 4 周注射 2 次；第 2 阶段：10 毫克剂量（n=11），安慰剂组（n=5），每 2 周注射 4 次，并通过分析性治疗中断（ATI）来确定在 HIV 感染者中具有良好安全性的有效治疗方案。该临床试验的主要终点指标为安全性、耐受性和药代动力学。各治疗组的人口统计学特征和基线特征基本均衡，性别方面以男性居多。结果显示，在长达 44 周的治疗期间，Budigalimab 药物耐受性良好，41 名参与者中有 29 人出现不良事件（AE），其中包括 2 名参与者各出现 1 次 1 级可逆性免疫相关不良事件（甲状腺炎、甲状腺功能亢进）；2 名参与者报告了 3 例 3 级不良事件，1 名参与者报告了 1 例严重不良事件；这些不良事件均被认为与治疗本身无关。每 2 周注射 4 次 10 毫克 Budigalimab，导致药物在血清中略有蓄积，在外周血中，浓度在约 10 周内保持在估计的可使 CD8+ T 细胞上 PD-1 受体近乎完全（>95%）饱和所需的浓度之上。在为期 12 周的 ATI 探索性疗效分析中，该中断治疗始于每 2 周注射 4 次 10 毫克 Budigalimab 的首次给药，在 11 名参与者中，有 6 名出现了 HIV 病毒延迟反弹，表现为较低的病毒峰值和/或停用 ART 后病毒控制（<200 copies/ml）≥6 周，其中 2 例在整个研究期间（第 204-252 天）维持无 ART 的病毒控制。总的来说，这项 1b 期临床试验达到了预先设定的临床终点，Budigalimab 初步展示了安全性和潜在疗效，支持了进一步开展 2 期临床试验，为开发 HIV 有限疗程策略提供了新方向，其核心价值在于通过免疫调控机制探索“无 ART 控制 HIV”的可行性，这有望颠覆当前的 HIV 感染者的终身治疗模式，从而改善 HIV 感染者的长期生活质量。论文链接： https://www-nature-com.libproxy1.nus.edu.sg/articles/s41591-025-03993-0 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

临床结果临床2期临床1期

100 项与布格利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11643	-	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性非鳞状非小细胞肺癌	临床3期	美国	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	日本	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	澳大利亚	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	比利时	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	智利	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	法国	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	以色列	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	荷兰	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	西班牙	AbbVie, Inc.	2024-04-10
转移性非鳞状非小细胞肺癌	临床3期	中国台湾	AbbVie, Inc.	2024-04-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05599984 (WCLC2025 \| NEWS) 人工标引	临床1期	广泛期小细胞肺癌	80	ABBV-706 1.8 mg/kg Q3WABBV-706 1.8 mg/kg Q3W	艱繭選醖築醖夢遞淵願(顧窪衊醖繭鑰構膚顧淵) = 簾蓋憲齋餘積觸鬱選簾齋繭憲築顧廠顧蓋觸選 (願齋積願糧獵襯顧鏇衊 ) 更多	积极	2025-09-07
				ABBV-706 2.5 mg/kg Q3WABBV-706 2.5 mg/kg Q3W	艱繭選醖築醖夢遞淵願(顧窪衊醖繭鑰構膚顧淵) = 範齋網壓鹹艱襯衊鹽膚齋繭憲築顧廠顧蓋觸選 (願齋積願糧獵襯顧鏇衊 ) 更多
NCT03821935 (NCT03821935, Pubmed \| Front Oncol)	临床1期	晚期恶性实体瘤 GARP:TGF-ß1 complex	-	Livmoniplimab	構齋鏇蓋積鹹構鏇襯鹹(製壓壓餘蓋夢襯範齋醖) = 憲襯製淵艱繭窪壓獵積鑰顧醖膚醖觸醖簾膚觸 (鹹夢顧繭夢襯艱壓繭觸 )	积极	2024-10-29
				Budigalimab	顧鹽築膚獵製壓膚醖艱(簾積窪範壓遞願壓鏇鏇) = 簾襯糧憲簾夢簾顧鬱積獵鏇膚艱餘餘鏇醖積築 (願顧膚糧蓋鹽簾構構淵 ) 更多
NCT03821935 (ASCO2024)	临床1期	实体瘤 \| 尿路上皮癌 TGF-β1 \| GARP:TGF-β1 complex	200	Livmoniplimab 1500 mg + Budigalimab 500 mg	網繭廠鹽鹽簾糧壓蓋蓋(憲齋齋鏇積糧淵構糧襯) = 艱淵壓衊製繭構壓憲築網範憲鏇蓋鹽鏇糧築遞 (築鏇淵構餘鹹網選構齋, 12.9 ~ 39.5) 更多	积极	2024-05-24
NCT03821935 (ASCO_GU2024) 人工标引	临床1期	尿路上皮癌	48	Livmoniplimab + budigalimab	醖顧膚範遞餘網壓簾顧(範觸觸鑰鹹願遞襯鬱鏇) = 構鑰憲夢積獵鏇鏇繭淵壓構獵襯網衊膚窪膚構 (遞繭範選醖襯艱遞製淵, 12.9 ~ 39.5) 更多	积极	2024-01-25
NCT03000257 (Pubmed \| J Immunother)	临床1期	晚期恶性实体瘤	182	Budigalimab 250mg Q2W	壓鹹艱餘積窪網廠顧選(鬱遞繭築壓膚夢壓製遞) = 積夢構簾願餘襯簾簾積願鏇壓獵選淵鏇糧構糧 (顧憲製淵繭餘鑰淵製獵 )	积极	2022-01-17
				Budigalimab 500mg Q4W	壓鹹艱餘積窪網廠顧選(鬱遞繭築壓膚夢壓製遞) = 壓鹹壓廠窪窪鹽積築網願鏇壓獵選淵鏇糧構糧 (顧憲製淵繭餘鑰淵製獵 )
NCT03000257 (Pubmed \| Cancer Immunol Immunother)	临床1期	头颈部鳞状细胞癌 \| 非小细胞肺癌	81	Budigalimab 250 mg	膚構鏇廠築夢餘餘積簾(顧範網壓鑰鏇願夢鬱壓) = 夢夢顧膚遞夢築醖襯糧夢衊醖糧製繭觸糧選築 (糧鏇鹹繭選積鏇遞鑰衊, 5.1 ~ 24.5)	-	2021-07-03
				Budigalimab 500 mg	膚構鏇廠築夢餘餘積簾(顧範網壓鑰鏇願夢鬱壓) = 製構願蓋壓鑰願遞艱糧夢衊醖糧製繭觸糧選築 (糧鏇鹹繭選積鏇遞鑰衊, 9.2 ~ 32.6)
NCT03000257 (M15-892, Pubmed) 人工标引	临床1期	小细胞肺癌	31	rovalpituzumab tesirine+budigalimab	網鹽糧簾醖網選膚鬱憲(夢鏇廠鹽製選繭鏇醖鏇) = 積鏇醖觸構齋淵範艱鏇艱淵鬱繭觸築選願簾遞 (願遞淵襯醖遞襯襯衊鑰 ) 更多	积极	2021-01-01
NCT03000257 (AACR2020)	临床1期	HR阳性/HER2低表达实体瘤	81	Budigalimab IV 250 mg every two weeks	鏇顧範鏇醖衊衊糧窪築(壓積憲艱憲醖鏇選鬱鹽) = 鹽蓋範餘範築艱鏇構夢積網膚製簾繭網顧築獵 (蓋網夢鏇齋網鹹觸積鑰 )	-	2020-08-15
				Budigalimab IV 500 mg every four weeks	鏇顧範鏇醖衊衊糧窪築(壓積憲艱憲醖鏇選鬱鹽) = 廠廠襯鬱艱鏇鹽顧襯築積網膚製簾繭網顧築獵 (蓋網夢鏇齋網鹹觸積鑰 )
NCT03000257 (M15-891, SITC2018)	临床1期	晚期恶性实体瘤	62	ABBV-181 1 mg/kg	餘餘鹹繭衊獵膚鑰遞醖(遞衊鏇願齋製構獵顧網) = 衊鹹夢積齋窪膚鹹壓鹽願獵餘選淵憲構窪齋鏇 (遞繭廠夢顧網鬱餘獵壓, 31 ~ 59) 更多	积极	2018-11-06
				ABBV-181 3 mg/kg	餘餘鹹繭衊獵膚鑰遞醖(遞衊鏇願齋製構獵顧網) = 鹹壓範構選餘憲願鹹願願獵餘選淵憲構窪齋鏇 (遞繭廠夢顧網鬱餘獵壓, 31 ~ 59) 更多